May 18, 2020 / 8:07 PM / 18 days ago

Roche's Tecentriq wins FDA approval as first-line therapy for some lung cancer forms

May 18 (Reuters) - Swiss drugmaker Roche Holding AG’s Genentech unit said on Monday the U.S. Food and Drug Administration has approved Tecentriq as a standalone therapy for an advanced form of lung cancer.

Tecentriq has won the agency's approval for use in previously untreated adults with certain types of metastatic non-small cell lung cancer, the company said. (reut.rs/2ZcrfxH) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below